The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability

被引:31
|
作者
Dickie, Ben R. [1 ,2 ]
Rose, Chris J. [3 ]
Kershaw, Lucy E. [1 ,2 ]
Withey, Stephanie B. [4 ]
Carrington, Bernadette M. [5 ]
Davidson, Susan E. [5 ]
Hutchison, Gillian [6 ]
West, Catharine M. L. [1 ]
机构
[1] Univ Manchester, Manchester Acad Hlth Sci Ctr, Div Mol & Clin Canc Sci, Manchester M20 4BX, Lancs, England
[2] Christie NHS Fdn Trust, Christie Med Phys & Engn, Manchester M20 4BX, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Imaging Sci, Div Informat Imaging & Data Sci, Manchester M13 9PG, Lancs, England
[4] Univ Hosp Birmingham NHS Fdn Trust, RRPPS, Birmingham B30 3HP, W Midlands, England
[5] Christie NHS Fdn Trust, Dept Diagnost Radiol, Manchester M20 4BX, Lancs, England
[6] Royal Bolton NHS Fdn Trust, Dept Radiol, Farnworth BL4 0JR, England
关键词
cervix cancer; DCE-MRI; prognostic biomarker; plasma flow; K-trans; permeability surface-area product; TUMOR OXYGENATION; NECK CANCER; PARAMETERS; CARCINOMA; PERFUSION; RADIOTHERAPY; SURVIVAL; MODELS; TRACER; HEAD;
D O I
10.1038/bjc.2017.121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The microvascular contrast agent transfer constant K-trans has shown prognostic value in cervical cancer patients treated with chemoradiotherapy. This study aims to determine whether this is explained by the contribution to K-trans of plasma flow (F-p), vessel permeability surface-area product (PS), or a combination of both. Methods: Pre-treatment dynamic contrast-enhanced MRI (DCE-MRI) data from 36 patients were analysed using the two-compartment exchange model. Estimates of F-p, PS, K-trans, and fractional plasma and interstitial volumes (v(p) and v(e)) were made and used in univariate and multivariate survival analyses adjusting for clinicopathologic variables tumour stage, nodal status, histological subtype, patient age, tumour volume, and treatment type (chemoradiotherapy vs radiotherapy alone). Results: In univariate analyses, F-p (HR = 0.25, P = 0.0095) and K-trans (HR = 0.20, P = 0.032) were significantly associated with disease-free survival while PS, v(p) and v(e) were not. In multivariate analyses adjusting for clinicopathologic variables, F-p and K-trans significantly increased the accuracy of survival predictions (P = 0.0089). Conclusions: The prognostic value of K-trans in cervical cancer patients treated with chemoradiotherapy is explained by microvascular plasma flow (F-p) rather than vessel permeability surface-area product (PS).
引用
收藏
页码:1436 / 1443
页数:8
相关论文
共 50 条
  • [1] The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant Ktrans in cervical cancer is explained by plasma flow rather than vessel permeability
    Ben R Dickie
    Chris J Rose
    Lucy E Kershaw
    Stephanie B Withey
    Bernadette M Carrington
    Susan E Davidson
    Gillian Hutchison
    Catharine M L West
    [J]. British Journal of Cancer, 2017, 116 : 1436 - 1443
  • [2] Preoperative Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Contrast Transfer Coefficient and Plasma Volume in Patients with Cerebral Gliomas
    Nguyen, T. B.
    Cron, G. O.
    Mercier, J. F.
    Foottit, C.
    Torres, C. H.
    Chakraborty, S.
    Woulfe, J.
    Jansen, G. H.
    Caudrelier, J. M.
    Sinclair, J.
    Hogan, M. J.
    Thornhill, R. E.
    Cameron, I. G.
    [J]. AMERICAN JOURNAL OF NEURORADIOLOGY, 2015, 36 (01) : 63 - 69
  • [3] Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer
    Weber, Jean-Philip Daniel
    Spiro, Judith Eva
    Scheffler, Matthias
    Wolf, Juergen
    Nogova, Lucia
    Tittgemeyer, Marc
    Maintz, David
    Laue, Hendrik
    Persigehl, Thorsten
    [J]. PLOS ONE, 2022, 17 (03):
  • [4] Assessment of vessel permeability by combining dynamic contrast-enhanced and arterial spin labeling MRI
    Liu, Ho-Ling
    Chang, Ting-Ting
    Yan, Feng-Xian
    Li, Cheng-He
    Lin, Yu-Shi
    Wong, Alex M.
    [J]. NMR IN BIOMEDICINE, 2015, 28 (06) : 642 - 649
  • [5] DYNAMIC CONTRAST-ENHANCED MRI IN DETERMINING HISTOLOGICAL TYPE OF CERVICAL CANCER
    Tarachkova, E., V
    Shorikov, M. A.
    Panov, V. O.
    Kuznetsov, V. V.
    Tyurin, I. E.
    Shimanovsky, N. L.
    [J]. BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY, 2016, (04): : 27 - 33
  • [6] Impact of contrast agent injection duration on dynamic contrast-enhanced MRI quantification in prostate cancer
    Klawer, Edzo M. E.
    van Houdt, Petra J.
    Pos, Floris J.
    Heijmink, Stijn W. T. P. J.
    van Osch, Matthias J. P.
    van der Heide, Uulke A.
    [J]. NMR IN BIOMEDICINE, 2018, 31 (09)
  • [7] Dynamic contrast enhanced MRI (DCE MRI) for assessment of effects of anti-angiogenic therapy: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameters model
    Thng, C. H.
    Koh, T. S.
    Rumpel, H.
    Khoo, J. B.
    Ong, A. B.
    Sukri, N.
    Tai, B. C.
    Soo, R. A.
    Humerickhouse, R.
    Goh, B. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Dynamic contrast enhanced MRI (DCE MRI) for Phase I anti-angiogenic trial: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameter model
    Thng, C. H.
    Hartono, S.
    Koh, T. S.
    Rumpel, H.
    Ong, A. B.
    Sukri, N.
    Tai, B. C.
    Soo, R. A.
    Humerickhouse, R.
    Goh, B. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Value of Dynamic Contrast-Enhanced MRI and Correlation with Tumor Angiogenesis in Bladder Cancer
    Tuncbilek, Nermin
    Kaplan, Mustafa
    Altaner, Semsi
    Atakan, Irfan H.
    Sut, Necdet
    Inci, Osman
    Demir, Mustafa Kemal
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 192 (04) : 949 - 955
  • [10] Is a quantitative analysis of dynamic contrast-enhanced MRI of added value for prostate cancer diagnosis?
    Turco, S.
    Fernandes, Dinis C.
    Miclea, R.
    Schoots, I. G.
    Nooijen, P.
    Van der Linden, H.
    Barentsz, J.
    Heijmink, S.
    Wijkstrah, H.
    Mischi, M.
    [J]. EUROPEAN UROLOGY, 2022, 81 : S706 - S707